Login to Your Account



RxDx: Achieving the End Goal for Personalized Medicine

By Catherine Hollingsworth


Monday, February 9, 2009
Ten years ago, Genentech's Herceptin stood alone as the first drug required to be paired with a genetic test to determine which patients are likely respond to the cancer therapy. Now, a new crop of so-called companion diagnostics are emerging - including KRAS and EGF mutation tests, for example - that would serve a similar purpose to the HER2 test kits.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription